Confirmatory validation of the french version of the Duchenne Muscular Dystrophy module of the pediatric quality of life inventory (PedsQLTM3.0DMDfv).

Duchenne Muscular Dystrophy (DMD) is a neuromuscular disease that inevitably leads to total loss of autonomy. The new therapeutic strategies aim to both improve survival and optimise quality of life. Evaluating quality of life is nevertheless a major challenge. No DMD-specific quality of life scale to exists in French. We therefore produced a French translation of the English Duchenne Muscular Dystrophy module of the Pediatric Quality of Life Inventory (PedsQLTMDMD) following international recommendations. The study objective was to carry out a confirmatory validation of the French version of the PedsQLTMDMD for paediatric patients with DMD, using French multicentre descriptive cross-sectional data. The sample consisted of 107 patients. Internal consistency was acceptable for proxy-assessments, with Cronbach's alpha coefficients above 0.70, except for the Treatment dimension. For self-assessments, internal consistency was acceptable only for the Daily Activities dimension. Our results showed poor metric qualities for the French version of the PedsQLTMDMD based on a sample of about 100 children, but these results remained consistent with those of the original validation. This confirms the interest of its use in clinical practice.

Program Report: KidneyPRO, a Web-based Training Module for Patient Engagement in Kidney Research.

PURPOSE OF REPORT: Over the recent years, there has been increasing support and traction for patient-oriented research (POR). Such an approach ensures that health research is focused on what matters most: improving outcomes for patients. Yet the realm of health research remains enigmatic for many patients in Canada who are not familiar with research terms and practices, highlighting the need for focused capacity-building efforts, including the development of novel educational tools to support patients to meaningfully engage in the research enterprise. The need for disease-specific training in POR was identified by the network dedicated to advancing patient-oriented kidney research in Canada, Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD), during the early years of the network's inception. In this report, we describe the development of KidneyPRO, an online learning module that orients patients and families to kidney research in Canada, and outlines ways to get involved. In line with the Patient Engagement framework of the Strategy for Patient Oriented Research, KidneyPRO was co-developed with the network's patient partners. SOURCES OF INFORMATION: The need for KidneyPRO was identified through a review of feedback from network participants of Canadian Institutes of Health Research's (CIHR) Foundations in Patient-Oriented Research Module 2-Health Research in Canada and a network-wide survey of Can-SOLVE CKD that was conducted in June 2017 and assessed training needs of key stakeholders. This 2017 survey ranked the need for tools providing introductory knowledge on Canadian kidney research as third in the network's top 5 capacity-building priorities. METHODS: At Can-SOLVE CKD, a dedicated multi-stakeholder team was formed from the Training & Mentorship Committee (the network's core infrastructure for POR capacity building) to determine the learning objectives, content, and user interface. The team consisted of 3 patient partners, Director of Research for the Kidney Foundation of Canada, a kidney clinician-scientist, the network's Patient Partnerships & Training Lead, Can-SOLVE CKD's Indigenous People's Engagement and Research Council Coordinator, and a project coordinator. With permission, content from CIHR's Foundations in Patient-Oriented Research, along with resources from the Kidney Foundation of Canada's research arm and network project teams, was used to form the basis of the tool. The working group adapted a DoTTI (Design and develOpment, Testing early iterations, Testing for Effectiveness, Integration, and implementation) framework and iteratively identified, created, and refined the content and user interface in consultation with the Training and Mentorship Committee and the Can-SOLVE CKD Patient Governance Circle. KEY FINDINGS: In this article, we describe the development, deployment, and evaluation of KidneyPRO, a web-based training module that helps patients understand general, patient-oriented, and kidney-specific research within Canada. KidneyPRO aims to support patient engagement in studies as partners and/or participants and empower them to take part in the research process in an active and meaningful way. It was co-designed and vetted by patients, which helps to ensure clear, useful content and a user-friendly interface. In addition, the module includes links to kidney research opportunities within the Can-SOLVE CKD Network and beyond. A literature review established that KidneyPRO fills an important gap in kidney-specific POR. Ongoing collection of website metrics and postcompletion surveys from users will be used to evaluate the effectiveness of the tool. LIMITATIONS: As an online tool, people who do not have adequate Internet access will not be able to use KidneyPRO. Currently, the tool is not compliant with all Web Content Accessibility Guidelines. Given how the landscape of patient partnership in research is constantly evolving, the content in KidneyPRO needs to be updated on a regular basis. IMPLICATIONS: Canadians with or at high risk of CKD now have access to an educational tool when seeking to engage as partners and/or participants in innovative kidney research.

OBJET DU RAPPORT: Depuis quelques années, la recherche axée sur le patient (RAP) bénéficie d'un soutien et d'un attrait croissant. Cette approche permet de garantir que la recherche se concentre sur ce qui compte vraiment: améliorer les résultats des patients. La recherche en santé demeure toutefois énigmatique pour les nombreux patients canadiens qui ne sont pas familiers avec la terminologie et les pratiques de la recherche. Ce constat met en évidence le besoin d'efforts ciblés pour renforcer les capacités, notamment en développant des outils éducatifs pour inciter les patients à s'impliquer significativement dans la recherche. Le besoin de formation spécifique aux maladies rénales dans la RAP a été identifié par Can-SOLVE CKD, le réseau dédié à l'avancement de la recherche en santé rénale axée sur le patient au Canada, dès les premières années de sa création. Dans ce rapport, nous discutons du développement de KidneyPRO, un module d'apprentissage en ligne qui oriente les patients et les familles vers la recherche en santé rénale au Canada et qui présente les différentes façons de s'impliquer. Conformément au Cadre d'engagement des patients de la Stratégie de recherche axée sur le patient, KidneyPRO a été élaboré avec la participation des patients-partenaires du réseau. SOURCES: Le besoin pour un outil comme KidneyPRO a été établi grâce à l'examen des commentaires des participants au module 2 des fondements de la recherche axée sur le patient des IRSC et d'un sondage évaluant les besoins de formation des principaux intervenants mené en juin 2017 dans l'ensemble du réseau Can-SOLVE CKD. Ce sondage a permis de classer le besoin d'outils fournissant des connaissances de base sur la recherche en santé rénale au Canada au troisième rang des cinq principales priorités du réseau en matière de renforcement des capacités. MÉTHODOLOGIE: Chez Can-SOLVE CKD, une équipe multipartite dédiée a été constituée au sein du comité de formation et de mentorat (la principale infrastructure du réseau en matière de renforcement des capacités dans la RAP) pour établir les objectifs d'apprentissage, le contenu et l'interface utilisateur de KidneyPRO. Cette équipe était constituée de trois patients-partenaires, du directeur de la recherche de la Fondation canadienne du rein, d'un chercheur clinicien en santé rénale, du responsable chez Can-SOLVE CKD de la formation et des partenariats avec les patients, du coordonnateur du Conseil de la recherche et de l'engagement des peuples autochtones (CREPC) de Can-SOLVE CKD, et d'un coordonnateur de projet. Avec les autorisations requises, le contenu des Fondations pour la recherche axée sur le patient des IRSC, de même que les ressources du bras de recherche de la Fondation canadienne du rein et des équipes de projet de Can-SOLVE CKD ont été utilisés pour constituer la base de l'outil. Le groupe de travail a adapté un cadre de perfectionnement DoTTI (Design and develOpment, Testing early iterations, Testing for Effectiveness, Integration and implementation) puis déterminé, créé et raffiné de manière itérative le contenu et l'interface utilisateur de l'outil en collaboration avec le Comité de formation et de mentorat et le Conseil des patients de Can-SOLVE CKD. PRINCIPAUX RÉSULTATS: Cet article décrit le développement, le déploiement et l'évaluation de KidneyPRO, un module d'apprentissage en ligne qui aide les patients canadiens à comprendre la recherche tant générale que centrée sur les patients ou spécifique aux maladies rénales. KidneyPRO est conçu pour soutenir l'engagement des patients en recherche, comme partenaires et/ou participants, et leur donner les moyens de s'impliquer activement et significativement dans le processus. L'outil a été co-créé et validé par les patients, ce qui contribue à garantir un contenu clair et pertinent, et une interface facile à utiliser. Le module comprend également des liens vers les différentes avenues de la recherche dans le réseau Can-SOLVE CKD et ailleurs. Une revue de la littérature a permis de confirmer que KidneyPRO comble un important vide de la RAP en santé rénale. L'efficacité de l'outil sera évaluée par la collecte de données en continu sur le site Web et par des questionnaires de suivi proposés aux patients. LIMITES: KidneyPRO étant un outil en ligne, son utilisation pourrait constituer un enjeu pour les personnes dont l'accès à internet est inadéquat. Aussi, l'outil n'est toujours pas conforme à toutes les directives pour l'accessibilité aux contenus Web. Enfin, la situation des partenariats avec les patients en recherche étant en constante évolution, le contenu de KidneyPRO doit être mis à jour régulièrement. CONCLUSION: Les Canadiens atteints ou susceptibles d'évoluer vers l'insuffisance rénale chronique ont désormais accès à un outil éducatif lorsqu'ils cherchent à s'impliquer comme partenaires ou participants à des études innovantes en santé rénale.

X-linked myotubular myopathy: A prospective international natural history study.

OBJECTIVES: Because X-linked myotubular myopathy (XLMTM) is a rare neuromuscular disease caused by mutations in the MTM1 gene with a large phenotypic heterogeneity, to ensure clinical trial readiness, it was mandatory to better quantify disease burden and determine best outcome measures. METHODS: We designed an international prospective and longitudinal natural history study in patients with XLMTM and assessed muscle strength and motor and respiratory functions over the first year of follow-up. The humoral immunity against adeno-associated virus serotype 8 was also monitored. RESULTS: Forty-five male patients aged 3.5 months to 56.8 years were enrolled between May 2014 and May 2017. Thirteen patients had a mild phenotype (no ventilation support), 7 had an intermediate phenotype (ventilation support less than 12 hours a day), and 25 had a severe phenotype (ventilation support 12 or more hours a day). Most strength and motor function assessments could be performed even in very weak patients. Motor Function Measure 32 total score, grip and pinch strengths, and forced vital capacity, forced expiratory volume in the first second of exhalation, and peak cough flow measures discriminated the 3 groups of patients. Disease history revealed motor milestone loss in several patients. Longitudinal data on 37 patients showed that the Motor Function Measure 32 total score significantly decreased by 2%. Of the 38 patients evaluated, anti-adeno-associated virus type 8 neutralizing activity was detected in 26% with 2 patients having an inhibitory titer >1:10. CONCLUSIONS: Our data confirm that XLMTM is slowly progressive for male survivors regardless of their phenotype and provide outcome validation and natural history data that can support clinical development in this population. CLINICALTRIALSGOV IDENTIFIER: NCT02057705.

Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury.

Spinal cord injury (SCI) leads to robust Rho activation at the lesion site. Here, we demonstrate that BA-210, a cell-permeable fusion protein derived from C3 transferase, formulated in fibrin sealant and delivered topically onto the dura matter, diffuses into the spinal cord and inactivates Rho in a dose-dependent manner. Treatment with BA-210 in rats with thoracic spinal cord contusion increased tissue sparing around the lesion area and led to significant improvement of locomotor function. In mice, BA-210 improved functional outcome when treatment was either applied at the time of injury or delayed by 24 h. In both rats and mice, treatment with BA-210 was well tolerated. Rats gained body weight normally, and BA-210 treatment had no impact on the development of allodynia. Inactivating Rho with BA-210 holds promise for treating patients with SCI.

Heat shock inactivates cellular antioxidant defenses against hydrogen peroxide: protection by glucose.

Hyperthermia is used in cancer treatment and potentiates the cytotoxicity of radiation and certain chemotherapy drugs. The mechanism(s) of heat killing and those involved in heat potentiation of cytotoxic modalities are not understood. This study examines whether heat shock causes a redox imbalance, leading to oxidative changes in Chinese hamster ovary cells. Decreases in the GSH/GSSG ratio reflected an oxidative imbalance in heated (42 degrees C) and in H(2)O(2)-challenged cells. Glucose provided protection against these changes. Glucose also protected cells against cytotoxicity of H(2)O(2) and/or hyperthermia (42 to 43 degrees C). Glucose appears to protect cells against H(2)O(2) and heat shock by providing NADPH through its metabolism via the pentose phosphate cycle (PC). When cells were deprived of glucose, there was a marked decrease in the GSH/GSSG ratio and in NADPH levels, indicating a severe redox imbalance. Glucose deprivation caused cell death, which was consistent with increased accumulation of H(2)O(2), since three distinct H(2)O(2)-detoxifying systems (N-acetyl-L-cysteine, sodium pyruvate, and catalase) rescued cells against cytotoxicity. Nontoxic levels of H(2)O(2) stimulated a corresponding increase in both PC activity and NADPH levels. NADPH levels and basal activity of the PC increased at 42 degrees C. However, the oxidant-stimulated increases in PC activity and NADPH levels were lost in heated cells. Therefore, heat shock inactivates an important cellular defense mechanism against oxidants. These findings suggest that heat shock may enhance the cytotoxicity of oxidants by inhibiting increases in PC activity following oxidative stress. These data are potentially relevant to understanding the potentiation of cytotoxicity of radiation and oxidant-generating drugs by heat shock, used in combined modality cancer treatment.